Your browser doesn't support javascript.
loading
Seven years of Non-invasive Follicular Thyroid Neoplasm with Papillary-like Nuclear Features (NIFTP): Rate of Acceptance and Variation of Diagnostic Approaches Across Different Continents.
Williams, Michelle D; Liu, Zhiyan; Rossi, Esther Diana; Agarwal, Shipra; Ryska, Ales; Ghuzlan, Abir Al; Bychkov, Andrey; Baloch, Zubair; Chernock, Rebecca; Chiosea, Simion L; Cipriani, Nicole A; Erkilic, Suna; Fridman, Michael; Hang, Jen-Fan; Harahap, Agnes Stephanie; Jung, Chan Kwon; Kakudo, Kennichi; Khalil, Moosa; Khanafshar, Elham; Kumarasinghe, Priyanthi; Lloyd, Ricardo; Nguyen, Truong Phan-Xuan; Ocal, Idris Tolgay; Prasad, Manju L; Pusztaszeri, Marc; Rana, Chanchal; Sadow, Peter; Sajed, Dipti P; Seethala, Raja; Tallini, Giovanni; Vuong, Huy Gia; Yegen, Gülçin; LiVolsi, Virginia A; Nikiforov, Yuri E.
Afiliación
  • Williams MD; Department of Anatomical Pathology, University of Texas MD Anderson Cancer Center, Houston, TX 77030, USA.
  • Liu Z; Department of Pathology, Shanghai Sixth People's Hospital, Shanghai 201306, China.
  • Rossi ED; Division of Anatomic Pathology and Histology, Fondazione Policlinico "Agostino Gemelli"-IRCCS, Università Cattolica del Sacro Cuore, Rome 00168, Italy.
  • Agarwal S; Department of Pathology, All India Institute of Medical Sciences, New Delhi 110029, India.
  • Ryska A; The Fingerland Department of Pathology, Charles University Medical Faculty and University Hospital, Hradec Kralove 50005, Czech Republic.
  • Ghuzlan AA; Department of Medical Biology and Pathology, Institute Gustave Roussy, Villejuif 94800, France.
  • Bychkov A; Department of Pathology, Kameda Medical Center, Kamogawa, Chiba 296-8602, Japan.
  • Baloch Z; Department of Pathology & Laboratory Medicine, University of Pennsylvania Medical Center, Perelman School of Medicine, Philadelphia, PA 19104, USA.
  • Chernock R; Department of Pathology and Immunology, Washington University School of Medicine, St Louis, MO 63110, USA.
  • Chiosea SL; Department of Pathology, University of Pittsburgh Medical Center, Pittsburgh, PA 15213, USA.
  • Cipriani NA; Department of Pathology, The University of Chicago, Chicago, IL 60637, USA.
  • Erkilic S; Department of Pathology, Faculty of Medicine, Gaziantep University, Gaziantep 27310, Turkey.
  • Fridman M; Department of Oncology, Belarus Medical State University, Minsk 220116, Belarus.
  • Hang JF; Department of Pathology and Laboratory Medicine, Taipei Veterans General Hospital, Taipei 11217, Taiwan.
  • Harahap AS; Department of Anatomical Pathology, Universitas Indonesia, Dr. Cipto Mangunkusumo Hospital, Jakarta 10430, Indonesia.
  • Jung CK; Department of Hospital Pathology, College of Medicine, The Catholic University of Korea, Seoul 06591, Republic of Korea.
  • Kakudo K; Department of Pathology, Cancer Genome Center and Thyroid Disease Center, Izumi City General Hospital, Izumi, Osaka 594-0073, Japan.
  • Khalil M; Department of Pathology, University of Calgary, Calgary, Alberta T2N 2T9, Canada.
  • Khanafshar E; Department of Pathology, University of California San Francisco, San Francisco, CA 94143, USA.
  • Kumarasinghe P; Department of Pathology, University of Western Australia & Curtain Medical School, Perth, Western Australia 6102, Australia.
  • Lloyd R; Department of Pathology and Laboratory Medicine, University of Wisconsin School of Medicine and Public Health, Madison, WI 53705, USA.
  • Nguyen TP; Department of Pathology, Chulalongkorn University, Bangkok 10330, Thailand.
  • Ocal IT; Department of Pathology and Laboratory Medicine, Mayo Clinic Arizona, Scottsdale, AZ 85259, USA.
  • Prasad ML; Department of Pathology, Yale School of Medicine, New Haven, CT 06510, USA.
  • Pusztaszeri M; Department of Pathology, McGill University, Montreal, Quebec H3T 1E2, Canada.
  • Rana C; Department of Pathology, King George's Medical University, Lucknow 226003, India.
  • Sadow P; Department of Pathology, Massachusetts General Hospital, Boston, MA 02114, USA.
  • Sajed DP; Department of Pathology and Laboratory Medicine, University of California, Los Angeles, Los Angeles, CA 90095, USA.
  • Seethala R; Department of Pathology, University of Pittsburgh Medical Center, Pittsburgh, PA 15213, USA.
  • Tallini G; Anatomic Pathology-Department of Medical and Surgical Sciences (DIMEC), University of Bologna; Solid Tumor Molecular Pathology Laboratory, IRCCS Azienda Ospedaliero, University of Bologna, Bologna 40138, Italy.
  • Vuong HG; Department of Pathology, University of Iowa Hospitals and Clinics, Iowa City, IA 52242, USA.
  • Yegen G; Department of Pathology, Medical Faculty of Istanbul, Istanbul University, 34093 Istanbul, Turkey.
  • LiVolsi VA; Department of Pathology & Laboratory Medicine, University of Pennsylvania Medical Center, Perelman School of Medicine, Philadelphia, PA 19104, USA.
  • Nikiforov YE; Department of Pathology, University of Pittsburgh Medical Center, Pittsburgh, PA 15213, USA.
J Clin Endocrinol Metab ; 2024 Jun 14.
Article en En | MEDLINE | ID: mdl-38874075
ABSTRACT
CONTEXT Noninvasive follicular thyroid neoplasm with papillary-like nuclear features (NIFTP) was introduced as a new entity replacing the diagnosis of noninvasive encapsulated follicular variant of papillary thyroid carcinoma (PTC). Significant variability in the incidence of NIFTP diagnosed in different world regions has been reported.

OBJECTIVE:

To investigate the rate of adoption of NIFTP, change in practice patterns, and uniformity in applying diagnostic criteria among pathologists practicing in different regions.

METHODS:

Two surveys distributed to pathologists of the International Endocrine Pathology Discussion Group with multiple-choice questions on NIFTP adoption into pathology practice and whole slide images of 5 tumors to collect information on nuclear score and diagnosis. Forty-eight endocrine pathologists, including 24 from North America, 8 from Europe, and 16 from Asia/Oceania completed the first survey and 38 the second survey.

RESULTS:

A 94% adoption rate of NIFTP by the pathologists was found. Yet, the frequency of rendering NIFTP diagnosis was significantly higher in North America than in other regions (P = .009). While the highest concordance was found in diagnosing lesions with mildly or well-developed PTC-like nuclei, there was significant variability in nuclear scoring and diagnosing NIFTP for tumors with moderate nuclear changes (nuclear score 2) (case 2, P < .05). Pathologists practicing in North America and Europe showed a tendency for lower thresholds for PTC-like nuclei and NIFTP than those practicing in Asia/Oceania.

CONCLUSION:

Despite a high adoption rate of NIFTP across geographic regions, NIFTP is diagnosed more often by pathologists in North America. Significant differences remain in diagnosing intermediate PTC-like nuclei and respectively NIFTP, with more conservative nuclear scoring in Asia/Oceania, which may explain the geographic differences in NIFTP incidence.
Palabras clave
Texto completo
Añadir a Mi BVS
Imprimir
XML
PubMed Links
Buscar en Google

Texto completo: 1 Colección: 01-internacional Base de datos: MEDLINE Idioma: En Revista: J Clin Endocrinol Metab Año: 2024 Tipo del documento: Article País de afiliación: Estados Unidos Pais de publicación: Estados Unidos
Texto completo
Añadir a Mi BVS
Imprimir
XML
PubMed Links
Buscar en Google

Texto completo: 1 Colección: 01-internacional Base de datos: MEDLINE Idioma: En Revista: J Clin Endocrinol Metab Año: 2024 Tipo del documento: Article País de afiliación: Estados Unidos Pais de publicación: Estados Unidos